|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Biliary Atresia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Common variants of GPC1 gene were genetically involved in BA risk.
|
27373597 |
2016 |
|
Biliary Atresia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We observed a statistically significant increase in deletions at 2q37.3 in patients with BA that resulted in deletion of one copy of GPC1, which encodes glypican 1, a heparan sulfate proteoglycan that regulates Hedgehog signaling and inflammation.
|
23336978 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Remarkably, the enhanced expression of Notum, a conserved feedback antagonist of Wnt, was observed in tumors along with alterations in Glypican-1 and Glypican-3 levels.
|
26517809 |
2015 |
|
Congenital atresia of extrahepatic bile duct
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We observed a statistically significant increase in deletions at 2q37.3 in patients with BA that resulted in deletion of one copy of GPC1, which encodes glypican 1, a heparan sulfate proteoglycan that regulates Hedgehog signaling and inflammation.
|
23336978 |
2013 |
|
Congenital atresia of extrahepatic bile duct
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Common variants of GPC1 gene were genetically involved in BA risk.
|
27373597 |
2016 |
|
SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene.
|
10814714 |
2000 |
|
Simpson-Golabi-Behmel syndrome
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene.
|
10814714 |
2000 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
α3(V) chains are produced in both basal-like and luminal human breast tumours, and its expression levels are tightly coupled with those of glypican-1 across breast cancer types.
|
28102194 |
2017 |
|
Hepatomegaly
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Hypopituitarism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Hypothyroidism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-GPC1 mAb also inhibited tumor growth of GPC1 positive ESCC patients derived tumor xenograft models.
|
28445969 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proportion of cases by tumor type showing staining with glypican-1 and the H-score for each tumor type were evaluated.
|
29785020 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls.
|
31414945 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, glypican-1 antisense-expressing PANC-1 cells exhibited a significantly reduced ability to form tumors in nude mice in comparison with parental and sham-transfected PANC-1 cells.
|
10505759 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Paradoxical Role of Glypican-1 in Prostate Cancer Cell and Tumor Growth.
|
31391540 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This approach is clinically relevant as a companion test to the already available diagnostic tools, since patients with GPC1-positive exosomes in peripheral blood showed decreased tumor free survival.
|
31400579 |
2019 |
|
Ophthalmoplegia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Pruritus
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Seizures
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Splenomegaly
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Alkaline phosphatase raised
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Prothrombin time increased
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Eyelid Xanthoma
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|